Competing on a prescription drug like a GLP-1 is difficult. The real opportunity for entrepreneurs is in the surrounding ecosystem. This includes selling supplements to counteract muscle loss, providing nutritional counseling, and creating lifestyle management programs for patients using these drugs.

Weight-loss drugs like Ozempic have moved from a niche medical treatment to a mainstream phenomenon, with new data showing 15.2% of all American women are now taking them. This rapid, large-scale adoption signifies a major public health shift that will have downstream effects on the food, fitness, and healthcare industries.

The widespread adoption of GLP-1 drugs for obesity, projected to reach 25 million U.S. users, will significantly reduce food, soda, and alcohol consumption. This presents a material, long-term revenue threat to consumer-facing industries like fast food, snack companies, and even casinos, forcing investors in those sectors to adjust their models.

The widespread adoption of GLP-1 therapies is projected to decrease total U.S. calorie consumption by 1.6% by 2035. This second-order effect will create significant disruption and headwinds for industries reliant on consumer food purchasing, including the CPG, retail, and restaurant sectors.

The widespread use of GLP-1 drugs like Ozempic has a second-order effect: it dulls users' sense of taste. In response, food giant Nestlé is proactively changing its recipes, adding more salt and spices to brands like Cornflakes and Popsicles to cater to this large and growing consumer segment's altered taste profile.

The growth of energy drinks is largely incremental. While some consumers switch from coffee or soda, most new consumption represents an overall increase in caffeine intake. This effectively grows the entire market pie rather than simply re-slicing it, countering the common assumption of a zero-sum game.

Drugs like Ozempic shift consumer preference from simple carbs to high-protein foods. This has accelerated beef demand, as users crave items like beef jerky over chips. This counterintuitive trend links pharmaceuticals to agricultural commodity markets.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.

The blockbuster success of GLP-1 weight-loss drugs creates a large unmet need. Since these drugs cause significant loss of both fat and muscle, there is a massive emerging market for adjunctive therapies that can specifically build or preserve muscle mass in this growing patient population.